ACM
PSTV

Altium Capital Management’s Plus Therapeutics PSTV Stock Holding History

Altium Capital Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,757
Closed -$628K – 19
2025
Q3 		$628K Buy
+36,757
New +$451K 100% 1

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $149M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Altium Capital Management's PSTV Position: Q4 2025 in Review

Altium Capital Management sold out of Plus Therapeutics (PSTV) in Q4 2025, closing a stake of 36,757 shares — an estimated $628K sold.

Altium Capital Management first reported a position in PSTV in Q3 2025 and held it in 1 quarter. The position peaked at $628K in Q3 2025. 25 funds tracked by Wall St. Rank hold PSTV as of Q4 2025.

  • Altium Capital Management reported no remaining Plus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Altium Capital Management sold 36,757 Plus Therapeutics shares in Q4 2025, an estimated $628K.
  • Altium Capital Management first reported a position in Plus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Altium Capital Management's Plus Therapeutics position peaked at $628K in Q3 2025.
  • 25 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2025.

Based on Altium Capital Management's 13F filing for Q4 2025, filed 6 Feb 2026.